This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
MDMA
Replicated PTSD clinical signal (MAPS Phase 3) but FDA rejected the 2024 NDA.
Aliases (7)
Overview
What is MDMA?
Replicated PTSD clinical signal (MAPS Phase 3) but FDA rejected the 2024 NDA. Outside the clinical-trial context this is recreational use with cumulative serotonergic axon damage, post-acute depression, and adulteration risk. SKIP-PERMANENT for a 20yo with no PTSD indication.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Acute: jaw clenching (bruxism), pupil dilation, hyperthermia, hypertension, tachycardia, nausea, hyponatremia (over-hydration + ADH release).
- Post-acute: 3-5 day mood crash, irritability, cognitive fog.
- Chronic/cumulative: SERT density reduction, persistent depression in heavy users, cardiac valvulopathy theoretical (5-HT2B), neurocognitive deficits in heavy users (meta-analytic).
- Drug interactions: serotonin syndrome with SSRIs/SNRIs/MAOIs; potentially fatal.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.